Natera
Natera raises $200M Series E at $2.75B valuation
Quick Facts
Natera: Series E Funding Round
Natera has successfully raised $200M in Series E funding, reaching a valuation of $2.75B.
Company Overview
Cell-free DNA testing for cancer and pregnancy
Funding Details
The Series E round was led by Perceptive Advisors, with participation from Goldman Sachs.
Company Information
- Headquarters: San Carlos, CA
- Founded: 2003
- Employees: 2000+
- Category: Biotech
Investment
Natera plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Perceptive Advisors: Verified investor in Series E
- Goldman Sachs: Verified investor in Series E
Key Investors
About the Author
Related Company Reports
Arthrosi Therapeutics raises $153M Series E at $800M valuation
Arthrosi Therapeutics raises $153M in Series E at $800M valuation. Developing next-generation gout treatment drug for chronic conditions...
HorizonStudio Raises $100M Growth to Transform Biotech
HorizonStudio has secured $100M Growth in funding to accelerate growth and innovation. Leading artificial intelligence infrastructure enabling scalable ML deployment for businesses...
StreamData Raises $15M Seed to Transform Biotech
StreamData has secured $15M Seed in funding to accelerate growth and innovation. Leading artificial intelligence infrastructure enabling scalable ML deployment for businesses...
